pyrazinamide has been researched along with Adverse Drug Event in 16 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyrazinamide (PZA) is a key component of current and future regimens for tuberculosis (TB)." | 7.91 | The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol. ( Bonnett, LJ; Davies, GR; Mackay, EA; Millard, JD, 2019) |
| "Pyrazinamide (PZA) is a common drug that causes serious adverse events (SAEs)." | 5.56 | The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. ( Cho, YJ; Kim, Y; Kwon, BS; Lee, CT; Lee, JH; Lee, SH; Lee, YJ; Lim, SY; Park, JS; Yoon, HI, 2020) |
| "Hyperuricemia is frequently reported in adults, but there are few data for the pediatric population." | 5.42 | Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide? ( Aslan, AT; Budakoğlu, I; Şişmanlar, T, 2015) |
| "A number of pharmacological agents can induce hyperuricaemia, and sometimes gout, usually by interfering with the renal tubular excretion of urate but also in some instances by increasing the formation of uric acid." | 4.78 | Drug-induced gout. ( Scott, JT, 1991) |
| "Pyrazinamide (PZA) is a key component of current and future regimens for tuberculosis (TB)." | 3.91 | The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol. ( Bonnett, LJ; Davies, GR; Mackay, EA; Millard, JD, 2019) |
| "Standard treatment of active tuberculosis (TB) consists of isoniazid (INH), rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB)." | 3.74 | Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. ( Bruchet, N; Elwood, RK; Fitzgerald, JM; Marra, CA; Marra, F; Moadebi, S; Richardson, K, 2007) |
| "We used the Korea Adverse Event Reporting System (KAERS) database (2009-2018)." | 1.72 | Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System. ( Byeon, SJ; Choi, JH; Chung, SJ, 2022) |
| "Pyrazinamide (PZA) is a common drug that causes serious adverse events (SAEs)." | 1.56 | The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. ( Cho, YJ; Kim, Y; Kwon, BS; Lee, CT; Lee, JH; Lee, SH; Lee, YJ; Lim, SY; Park, JS; Yoon, HI, 2020) |
| "The currently preferred regimen for treatment of pulmonary tuberculosis (PTB) is isoniazid, rifampin, pyrazinamide, and ethambutol, which has been used either as separate tablets (ST) or as fixed-dose combination (FDC)." | 1.46 | Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. ( Al-Shaer, MH; Elewa, H; Iqbal, F; Mansour, H; Salameh, P, 2017) |
| "To assess outcome and adverse drug events with a standardised 12-month regimen for MDR-TB among second-line drug naïve patients." | 1.42 | High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. ( Abena Foe, JL; Aït-Khaled, N; Kuaban, C; Noeske, J; Rieder, HL; Trébucq, A, 2015) |
| "Hyperuricemia is frequently reported in adults, but there are few data for the pediatric population." | 1.42 | Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide? ( Aslan, AT; Budakoğlu, I; Şişmanlar, T, 2015) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Chung, SJ | 1 |
| Byeon, SJ | 1 |
| Choi, JH | 1 |
| Millard, JD | 1 |
| Mackay, EA | 1 |
| Bonnett, LJ | 1 |
| Davies, GR | 1 |
| Kwon, BS | 1 |
| Kim, Y | 1 |
| Lee, SH | 1 |
| Lim, SY | 1 |
| Lee, YJ | 1 |
| Park, JS | 1 |
| Cho, YJ | 1 |
| Yoon, HI | 1 |
| Lee, CT | 1 |
| Lee, JH | 1 |
| Bourhia, M | 1 |
| Ullah, R | 1 |
| S Alqahtani, A | 1 |
| Ibenmoussa, S | 1 |
| Khan, N | 1 |
| Mendonca, L | 1 |
| Dhariwal, A | 1 |
| Fontes, G | 1 |
| Menzies, D | 1 |
| Xia, J | 1 |
| Divangahi, M | 1 |
| King, IL | 1 |
| Kuaban, C | 1 |
| Noeske, J | 1 |
| Rieder, HL | 1 |
| Aït-Khaled, N | 1 |
| Abena Foe, JL | 1 |
| Trébucq, A | 1 |
| Şişmanlar, T | 1 |
| Aslan, AT | 1 |
| Budakoğlu, I | 1 |
| Al-Shaer, MH | 1 |
| Mansour, H | 1 |
| Elewa, H | 1 |
| Salameh, P | 1 |
| Iqbal, F | 1 |
| Joseph, P | 1 |
| Desai, VB | 1 |
| Mohan, NS | 1 |
| Fredrick, JS | 1 |
| Ramachandran, R | 2 |
| Raman, B | 1 |
| Wares, F | 1 |
| Thomas, A | 1 |
| Marra, F | 1 |
| Marra, CA | 1 |
| Bruchet, N | 1 |
| Richardson, K | 1 |
| Moadebi, S | 1 |
| Elwood, RK | 1 |
| Fitzgerald, JM | 1 |
| Scott, JT | 1 |
| Hart, FD | 1 |
1 review available for pyrazinamide and Adverse Drug Event
| Article | Year |
|---|---|
Drug-induced gout.
Topics: Cyclosporins; Cytotoxins; Diuretics; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Et | 1991 |
1 trial available for pyrazinamide and Adverse Drug Event
| Article | Year |
|---|---|
Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India.
Topics: Adult; Antibiotics, Antitubercular; Communicable Disease Control; Cycloserine; Directly Observed The | 2011 |
14 other studies available for pyrazinamide and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System.
Topics: Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Humans; Isoniazi | 2022 |
The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Meta-Analysis as Topic; Patient Safety; Pyr | 2019 |
The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis.
Topics: Aged; Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incide | 2020 |
Evidence of drug-induced hepatotoxicity in the Maghrebian population.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug-Related Side | 2022 |
Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug-Related Side Effects and Adverse | 2019 |
High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cameroon; Clofazimine; Cohort Studies; Confidence In | 2015 |
Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide?
Topics: Adolescent; Allopurinol; Antitubercular Agents; Child; Child, Preschool; Drug Administration Schedul | 2015 |
Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.
Topics: Adult; Antitubercular Agents; Diabetes Complications; Dose-Response Relationship, Drug; Drug Therapy | 2017 |
Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.
Topics: Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid; Pyrazinam | 2007 |
Drug-induced arthritis.
Topics: Acute Disease; Anticoagulants; Antihypertensive Agents; Arteritis; Arthritis; Barbiturates; Contrace | 1974 |